Overview

Treatment of Refractory Schizophrenia With Riluzole

Status:
Completed
Trial end date:
2006-08-29
Target enrollment:
Participant gender:
Summary
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotective medication riluzole is currently approved for treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease), a severe neurological illness. Due to its unique mechanism of action, riluzole, if effective in helping the symptoms of schizophrenia, would open novel directions in treatment of schizophrenia.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborator:
Stanley Medical Research Institute
Treatments:
Riluzole